SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celgene-CELG
CELG 108.240.0%Nov 22 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Bloxom who wrote (252)2/9/1999 11:14:00 PM
From: scaram(o)uche  Read Replies (1) of 804
 
For the record, BMY didn't pass on endostatin; ENMD wouldn't license it to BMY.

Bullshit. Miljenko, as usual, was correct. The BMY deal with ENMD gave them the right to sublicense anything that was derived from Children's. Bristol-Myers Squibb had right of first refusal with respect to both molecules, and it was well publicized when they passed on endo.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News